Clinical Trial: Treatment of Melasma With Glycolic Acid-Salicylic Acid Peel Versus Glycolic Acid Peel

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional

Official Title: Comparing the Efficacy and Safety of Combined Glycolic Acid and Salicylic Acid Peel Versus Glycolic Acid Peel Alone in the Treatment of Melasma: A Split Face Study

Brief Summary: The aim of this pilot study is to conduct a controlled comparison of the efficacy and safety of a combination peel (glycolic acid and salicylic acid) as compared to glycolic acid peel alone in the treatment of melasma. Our primary outcome is objective improvement in pigmentation as evaluated using a colorimeter. Our secondary outcomes are subjective improvement using the Melasma Area and Severity Index (MASI) and Patient and Physician Global assessment, as well as assessment of treatment tolerability and patient satisfaction.

Detailed Summary:

Melasma is an acquired form of hyperpigmentation that is seen most commonly on the face, characterized by symmetrically distributed brown patches of variable darkness. The cosmetically unattractive nature of this disorder has been shown to negatively affect a patient's quality of life. Unfortunately, the treatment of melasma is challenging and often disappointing. Treatment includes a combination approach with strict sun protection, cosmetic camouflage, topical lightening agents, laser therapy, and chemical peels.

Today, the investigators define chemical peeling as the application of chemical exfoliating agents to the skin, which results in destruction of one or more parts of the epidermis and/or dermis with subsequent regrowth of these layers. Chemical peels are divided into superficial (light), medium, and deep; with superficial peels being the focus of this study. Superficial peels penetrate into the epidermis only, and are a safe, widely available and well-tolerated treatment modality. These peeling agents include glycolic acid, lactic acid, mandelic acid, salicylic acid and trichloroacetic acid, each with unique properties. For instance, alpha-hydroxy acids, such as glycolic acid, are known to be hydrophilic, whereas salicylic acid is lipophilic and anti-inflammatory.

As each peeling agent has unique properties, it can be hypothesized that the combined use of these agents may result in better clinical outcomes than the use of an agent alone. Prior studies have demonstrated that the combined use of these peels are safe and effective in improving a variety of skin conditions including acne scars, hyperpigmentation, and infraorbital dark circles. Overall however, studies on the combined use of these chemical peels in the treatment of melasma are lacking.

Therefore, the ai
Sponsor: Boston Medical Center

Current Primary Outcome: Change in pigmentation [ Time Frame: Week 0, Week 7-8 (1-2 weeks following 4th peel), and Week 18 (12 weeks following 4th peel) ]

Change in pigmentation using a colorimeter


Original Primary Outcome: Change in pigmentation using a colorimeter [ Time Frame: Week 0, Week 7-8 (1-2 weeks following 4th peel), and Week 18 (12 weeks following 4th peel) ]

Current Secondary Outcome:

  • Change in pigmentation score [ Time Frame: Week 0, Week 7-8 (1-2 weeks following 4th peel), and Week 18 (12 weeks following 4th peel) ]
    Change in pigmentation using the Melasma Area and Severity Index (MASI)
  • Improvement of melasma [ Time Frame: Week 0 and Week 7-8 (1-2 weeks following 4th peel), and Week 18 (12 weeks following 4th peel) ]
    Improvement of melasma based on Patient and Physician Global assessment
  • Adverse events assessment [ Time Frame: Week 7-8 (1-2 weeks following 4th peel) ]
    Patient questionnaire to assess for any adverse events encountered


Original Secondary Outcome:

  • Change in pigmentation using the Melasma Area and Severity Index (MASI) score [ Time Frame: Week 0, Week 7-8 (1-2 weeks following 4th peel), and Week 18 (12 weeks following 4th peel) ]
  • Improvement of melasma based on Patient and Physician Global assessment [ Time Frame: Week 0 and Week 7-8 (1-2 weeks following 4th peel), and Week 18 (12 weeks following 4th peel) ]
  • Patient questionnaire to assess for any adverse events encountered [ Time Frame: Week 7-8 (1-2 weeks following 4th peel) ]


Information By: Boston Medical Center

Dates:
Date Received: October 28, 2015
Date Started: December 2017
Date Completion: February 2019
Last Updated: April 26, 2017
Last Verified: April 2017